Abstract
Purpose
To compare the short-term effect of treatment with atorvastatin and rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Methods
Sixty-nine patients with hypercholesterolemia were randomly assigned to receive 10 mg/day of atorvastatin or rosuvastatin for 12 weeks. Inflammatory biomarkers, including highsensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, matrix metalloproteinase-9 (MMP-9), and endothelin (ET-1), plasminogen activator inhibitor type 1 (PAI-1) and plasma tissue plasminogen activator (tPA), adiponectin, and lipid profiles were measured before and after statin therapy.
Results
Atorvastatin and rosuvastatin both lowered levels of hs-CRP, MMP-9, PAI-1, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) from baseline values, with rosuvastatin lowering TC and LDL-C to a greater extent than atorvastatin (P < 0.05). Adiponectin level increase was 15% higher than that at baseline with atorvastatin (P > 0.05) but 67% higher with rosuvastatin (P < 0.05).
Conclusions
Therapy with both statins not only significantly improved lipid profiles but also decreased levels of vascular biomarkers hs-CRP, MMP-9, and PAI-1; however, only rosuvastatin increased serum adiponectin levels significantly in patients with hypercholesterolemia, which could imply a beneficial effect in coronary artery disease.
Similar content being viewed by others
References
M. Matsubara, S. Maruoka, and S. Katayose. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87:2764–2769 (2002). doi:10.1210/jc.87.6.2764.
P.J. Havel. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 53(suppl 1):S143–151 (2004). doi:10.2337/diabetes.53.2007.S143.
M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry. Adiponectin: more than just another fat cell hormone? Diabetes Care. 26:2442–2450 (2003). doi:10.2337/diacare.26.8.2442.
T. Kadowaki, and T. Yamauchi. Adiponectin and adiponectin receptors. Endocr. Rev. 26:439–451 (2005). doi:10.1210/er.2005-0005.
K. Miyagishima, S. Hiramitsu, and S. Kato. Efficacy of atorvastatin therapy in ischaemic heart disease-effects on oxidized low-density lipoprotein and adiponectin. J. Int. Med. Res. 35:534–539 (2007).
K. K. Koh, M. J. Quon, S. H. Han, W. J. Chung, J. Y. Ahn, Y. H. Seo, I. S. Choi, and E. K. Shin. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol. 45:1649–1653 (2005). doi:10.1016/j.jacc.2005.02.052.
S. Wissen, T. J. Smilde, E. Groot, BA. Hutten, J. J. Kastelein, and A. F. Stalenhoef. The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Eur. J. Cardiovasc. Prev. Rehabil. 10:451–455 (2003). doi:10.1097/01.hjr.0000103277.02552.1e.
K. K. Koh, C. Cardillo, M. N. Bui, L. Hathaway, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. III Cannon. Vascular Effects of estrogen and cholesterol-lowering therapies on vascular function in hypercholesterolemic postmenopausal women. Circulation. 99:354–360 (1999).
R. C. Schlant, and R. W. Alexander. Hurst’s the heart: Arteries and veins. 8McGraw-Hill, New York, 1995.
A. Niemann-Jönsson, P. Dimayuga, S. Jovinge, F. Calara, M. P. S. Ares, G. N. Fredrikson, and J. Nilsson. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor- expression. Arterioscler. Thromb. Vasc. Biol. 20:2205–2211 (2000).
K. K. Ray, C. P. Cannon, and P. Ganz. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am. J. Cardiol. 98:18P–25P (2006). doi:10.1016/j.amjcard.2006.09.016.
G. G. Schwartz, A. G. Olsson, M. D. Ezekowitz, P. Ganz, M. F. Oliver, D. Waters, A. Zeiher, B. R. Chaitman, S. Leslie, and T. Stern. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:1711–1718 (2001). doi:10.1001/jama.285.13.1711.
T. C. Andrews, C. M. Ballantgne, J. A. Hsia, and J. H. Kramer. Achieving and maintaining National Cholesterol Education Program Low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111:185–191 (2001). doi:10.1016/S0002-9343(01)00799-9.
A. Cheng-Lai. Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Disease. 5:72–78 (2003). doi:10.1097/01.HDX.0000050417.89309.F8.
P. H. Jones, M. H. Davidson, E. A. Stein, H. E. Bays, J. M. McKenney, E. Miller, V. A. Cain, J. W. Blasetto, and STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Am. J. Cardiol. 92:152–160 (2003). doi:10.1016/S0002-9149(03)00530-7.
P. Libby, R. O. Bonow, D. L. Mann, D. P. Zipes, and E. Braunwald. Braunwald’s heart disease: A textbook of cardiovascular medicine. 8Saunders, USA, 2007.
S. H. Johnsen, E. B. Mathiesen, E. Fosse, O. Joakimsen, E. Stensland-Bugge, I. Njølstad, and E. Arnesen. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression. Circulation. 112:498–504 (2005). doi:10.1161/CIRCULATIONAHA.104.522706.
S. E. Nissen, E. M Tuzcu, P. Schoenhagen, T. Crowe, W. J. Sasiela, J. Tsai, J. Orazem, R. D. Magorien, C. O. 'Shaughnessy, P. Ganz, and the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352:29–38 (2005). doi:10.1056/NEJMoa042000.
G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687–692 (2001). doi:10.1038/89058.
T. Bourcier, and P. Libby. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:556–562 (2000).
A. Undas, K. E. Brummel-Ziedins, and K. G. Mann. Statins and blood coagulation. Arterioscler. Thromb. Vasc. Biol. 25:287–294 (2005). doi:10.1161/01.ATV.0000151647.14923.ec.
L. O. Jensen, P. Thayssen, K. E. Pedersen, S. Stender, and T. Haghfelt. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 110:265–270 (2004). doi:10.1161/01.CIR.0000135215.75876.41.
K. J. Molloy, M. M. Thompson, E. C. Schwalbe, P. R. Bell, A. R. Naylor, and I. M. Loftus. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am. J. Cardiol. 94:144–146 (2004). doi:10.1016/j.amjcard.2004.03.050.
J. Calles-Escandon, and M. Cipolla. Diabetes and endothelial dysfunction: A clinical perspective. Endocr. Rev. 22:36 (2001). doi:10.1210/er.22.1.36.
M. Crisby, G. Nordin-Fredriksson, P. K. Shah, J. Yano, J. Zhu, and J. Nilsson. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:926–933 (2001).
M. Juonala, J. S. Viikari, T. Laitinen, J. Marniemi, H. Helenius, T. Ronnemaa, and O. T. Raitakari. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns study. Circulation. 110:2918–2923 (2004). doi:10.1161/01.CIR.0000147540.88559.00.
S. H. Wilson, R. D. Simari, P. J. Best, T. E. Peterson, L. O. Lerman, M. Aviram, K. A. Nath, D. R. Jr Holmes, and A. Lerman. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 21:546–554 (2001). doi:10.1161/hq1101.097805.
J. K. Williams, G. K. Sukhova, D. M. Herrington, and P. Libby. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31:684–691 (1998). doi:10.1016/S0735-1097(97)00537-8.
I. V. Sergienko, E. I. U. Samoĭlenko, V. P. Masenko, M. V. Ezhov, A. B. Sumarokov, G. A. Tkachev, O. A. Pogorelova, T. V. Balakhonova, and V. G. Naumov. Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease. Kardiologiia. 46:4–8 (2006).
E. Ter Avest, E. J. Abbink, S. Holewijn, J. de Graaf, C. J. Tack, and A. F. Stalenhoef. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr. Med. Res. Opin. 21:1469–1476 (2005). doi:10.1185/030079905X61910.
R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801–809 (1993). doi:10.1038/362801a0.
D. M. Maahs, L. G. Ogden, G. L. Kinney, P. Wadwa, J. K. Snell-Bergeon, D. Dabelea, J. E. Hokanson, J. Ehrlich, R. H. Eckel, and M. Rewers. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 111:747–753 (2005). doi:10.1161/01.CIR.0000155251.03724.A5.
M. B. Schulze, E. B. Rimm, I. Shai, N. Rifai, and F. B. Hu. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care. 27:1680–1687 (2004). doi:10.2337/diacare.27.7.1680.
M. Cnop, P. J. Havel, K. M. Utzschneider, D. B. Carr, M. K. Sinha, E. J. Boyko, B. M. Retzlaff, R. H. Knopp, J. D. Brunzell, and S. E. Kahn. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 46:459–469 (2003).
T. Yamauchi, K. Hara, N. Kubota, Y. Terauchi, K. Tobe, P. Froguel, R. Nagai, and T. Kadowaki. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr. Drug Targets Immune. Endocr. Metabol. Disord. 3:243–254 (2003). doi:10.2174/1568008033340090.
C. -J. Li, H. -W. Sun, F. -L. Zhu, L. Chen, Y. -Y. Rong, Y. Zhang, and M. Zhang. Local Adiponectin treatment reduces atherosclerotic plaque size in rabbits. J. Endocrinol. 193:137–145 (2007). doi:10.1677/JOE-06-0173.
T. Pischon, C. J. Girman, G. S. Hotamisligil, N. Rifai, F. B. Hu, and E. B. Rimm. Plasma adiponectin levels and risk of myocardial infarction in men. J. Am. Med. Assoc. 291:1730–1737 (2004). doi:10.1001/jama.291.14.1730.
H. Chen, M. Montagnani, T. Funahashi, I. Shimomura, and M. J. Quon. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278:45021–45026 (2003). doi:10.1074/jbc.M307878200.
H. Kato, H. Kashiwagi, M. Shiraga, S. Tadokoro, T. Kamae, H. Ujiie, S. Honda, S. Miyata, Y. Ijiri, J. Yamamoto, N. Maeda, T. Funahashi, Y. Kurata, I. Shimomura, Y. Tomiyama, and Y. Kanakura. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol. 26:224–230 (2006). doi:10.1161/01.ATV.0000194076.84568.81.
G. A. Laughlin, E. Barrett-Connor, S. May, and C. Langenberg. Association of Adiponectin with coronary heart disease and mortality: The Rancho Bernardo study. Am. J. Epidemiol. 165:164–174 (2007). doi:10.1093/aje/kwk001.
S. Devaraj, D. Siegel, and I. Jialal. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am. J. Cardiol. 100:1397–1399 (2007). doi:10.1016/j.amjcard.2007.06.028.
I. Gouni-Berthold, H. K. Berthold, J. P. Chamberland, W. Krone, and C. S. Mantzoros. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. (Oxf). 68:536–541 (2008). doi:10.1111/j.1365-2265.2007.03080.x.
S. Sugiyama, H. Fukushima, K. Kugiyama, H. Maruyoshi, S. Kojima, T. Funahashi, T. Sakamoto, Y. Horibata, K. Watanabe, H. Koga, K. Sugamura, F. Otsuka, I. Shimomura, and H. Ogawa. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis. 194:e43–51 (2007). doi:10.1016/j.atherosclerosis.2006.08.023.
W. Mauser, N. Perwitz, B. Meier, M. Fasshauer, and J. Klein. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur. J. Pharmacol. 564:37–46 (2007). doi:10.1016/j.ejphar.2007.02.024.
J. Q. Li, S. P. Zhao, Q. Z. Li, Y. C. Cai, L. R. Wu, Y. Fang, and P. Li. Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. Clin. Chim. Acta. 370:57–62 (2006). doi:10.1016/j.cca.2006.01.024.
C. S. Chu, K. T. Lee, M. Y. Lee, H. M. Su, W. C. Voon, S. H. Sheu, and W. T. Lai. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am. J. Cardiol. 97:646–650 (2006). doi:10.1016/j.amjcard.2005.09.101.
Acknowledgements
This work was supported by The National Basic Research Program (973 Program) 2006CB503803 and HI-TECH Technique and Development Program of China (863 Program) 2007AA02Z448.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qu, Hy., Xiao, Yw., Jiang, Gh. et al. Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia. Pharm Res 26, 958–964 (2009). https://doi.org/10.1007/s11095-008-9798-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9798-6